Morgan Stanley on Acadia Pharmaceuticals (ACAD): 'we believe risk/reward remains skewed to the upside'
Tweet Send to a Friend
Morgan Stanley analyst Jeffrey Hung reiterated an Equalweight rating and $24.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
